Table 1.
Main characteristics of ESA and BSC patients in SPRESAS study.
| Patients and disease characteristics | ESAs (n = 530) | Best supportive care (n = 192) | p Value |
|---|---|---|---|
| Age (median) [p25–p75] | 77 years [70–80] | 76 years [68–81] | 0.042 |
| Gender | 530 | 192 | 0.398 |
| Male | 280 (54%) | 111 (58%) | |
| Female | 240 (46%) | 81 (42%) | |
| WHO 2008 | 413 | 121 | <0.001 |
| RCUD | 48 (11.6%) | 13 (10.7%) | |
| RCMD | 182 (44.1%) | 42 (34.7%) | |
| RARS | 101 (24.4%) | 14 (11.6%) | |
| RAEB-1 | 18 (4.4%) | 19 (15.7%) | |
| RAEB-2 | 2 (0.5%) | 11 (10%) | |
| MDS NOS | 3 (0.7%) | 0 (0%) | |
| MDS with del(5q−) | 17 (4.1%) | 10 (8.3%) | |
| CMML | 33 (8%) | 10 (8.3%) | |
| MDS/MPN | 7 (1.7%) | 2 (1.7%) | |
| Not available | 117 | 71 | |
| IPSS | 484 | 185 | <0.001 |
| Low | 305 (63%) | 74 (40%) | |
| Intermediate-1 | 179 (37%) | 111 (60%) | |
| Not available | 46 | 7 | |
| IPSS-R | 484 | 185 | <0.001 |
| Very low | 130 (26.9%) | 18 (9.7%) | |
| Low | 285 (58.9%) | 94 (50.8%) | |
| Intermediate | 63 (13%) | 57 (30.8%) | |
| High | 6 (1.2%) | 16 (8.6%) | |
| Not available | 46 | 7 | |
| Hemoglobin (median) [p25–p75] | 10 g/dl [9–10] | 9 g/dl [8–10] | <0.001 |
| Neutrophils (median) [p25–p75] | 2.74 × 109/l [1.6–4.0] | 2.58 × 109/l [1.6–4.3] | 0.742 |
| Platelets (median) [p25–p75] | 214 × 109/l [131–299] | 198.5 × 109/l [110–315] | 0.384 |
| Bone marrow blasts (median) [p25–p75] | 1% [0–2] | 3% [1–5] | <0.001 |
| EPO (median) [p25–p75] | 59.5 U/l [29.0–114.2] | 142.5 U/l [42.8–372.8] | 0.003 |
| Ferritin (median) [p25–p75] | 315 ng/ml [142–555] | 376 ng/ml [159–813] | 0.009 |
| Transfusion dependency | 329 | 192 | <0.001 |
| Yes | 185 (56.2%) | 184 (95.8%) | |
| No | 144 (43.8%) | 8 (4.2%) | |
| Not available | 201 | 0 | |
| Cytogenetics IPSS-R | 484 | 185 | 0.227 |
| Very good | 28 (5.8%) | 5 (2.7%) | |
| Good | 418 (86.5%) | 163 (88.1%) | |
| Intermediate | 37 (7.2%) | 14 (7.6%) | |
| Poor | 3 (0.6%) | 2 (1.1%) | |
| Very poor | 0 (0%) | 1 (0.5%) | |
| Not available | 46 | 7 | |
| ECOG | 74 | 9 | 0.200 |
| <1 | 59 (79.7%) | 5 (55.6%) | |
| ⩾2 | 15 (20.3%) | 4 (45.4%) |
CMML, chronic myelomonocytic leukemia; ECOG, Eastern Cooperative Oncology Group; ESA, erythropoietic stimulating agents; IPSS, international prognostic scoring system; IPSS-R, IPSS revised; MDS-U, myelodysplastic syndrome unclassifiable; MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasm; NOS, not otherwise specified; RAEB, refractory anemia with excess blasts; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia; SC, supportive care; SPRESAS, Spanish Registry of Erythropoietic Stimulating Agents Study.